Movement Alert｜KEYMED BIO-B Falls 5.38% in Regular Trading, CMG901 Phase III Positive Data Triggers Sell-the-News Pressure

Market Focus07-29

On July 29, KEYMED BIO-B fell 5.38% in regular trading, trading at 74.0 HKD/share with turnover of approximately 51.91 million HKD, extending the prior session's decline.

On the news front, the company previously announced that its CLDN18.2-targeting antibody-drug conjugate CMG901, co-developed with AstraZeneca, achieved positive topline results in the global Phase III CLARITY-Gastric01 trial. The study demonstrated statistically significant overall survival improvement in second-line and beyond CLDN18.2-positive advanced gastric cancer patients versus investigator's choice, with a safety profile consistent with prior studies and no new safety signals identified. The company projects peak annual sales of USD 3-5 billion for the drug.

Despite the strongly positive clinical data, the stock has exhibited a classic sell-the-news pattern, declining 5.59% on July 28 when results were announced and continuing lower, suggesting the market had already priced in the expected outcome ahead of the readout.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167820107?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-29 09:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167820107","market":"us","top_or_hot":-1,"title":"Movement Alert｜KEYMED BIO-B Falls 5.38% in Regular Trading, CMG901 Phase III Positive Data Triggers Sell-the-News Pressure","media":"Market Focus","content":"<p><p>On July 29, KEYMED BIO-B fell 5.38% in regular trading, trading at 74.0 HKD/share with turnover of approximately 51.91 million HKD, extending the prior session's decline.</p><p>On the news front, the company previously announced that its CLDN18.2-targeting antibody-drug conjugate CMG901, co-developed with AstraZeneca, achieved positive topline results in the global Phase III CLARITY-Gastric01 trial. The study demonstrated statistically significant overall survival improvement in second-line and beyond CLDN18.2-positive advanced gastric cancer patients versus investigator's choice, with a safety profile consistent with prior studies and no new safety signals identified. The company projects peak annual sales of USD 3-5 billion for the drug.</p><p>Despite the strongly positive clinical data, the stock has exhibited a classic sell-the-news pattern, declining 5.59% on July 28 when results were announced and continuing lower, suggesting the market had already priced in the expected outcome ahead of the readout.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜KEYMED BIO-B Falls 5.38% in Regular Trading, CMG901 Phase III Positive Data Triggers Sell-the-News Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜KEYMED BIO-B Falls 5.38% in Regular Trading, CMG901 Phase III Positive Data Triggers Sell-the-News Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-29 09:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 29, KEYMED BIO-B fell 5.38% in regular trading, trading at 74.0 HKD/share with turnover of approximately 51.91 million HKD, extending the prior session's decline.</p><p>On the news front, the company previously announced that its CLDN18.2-targeting antibody-drug conjugate CMG901, co-developed with AstraZeneca, achieved positive topline results in the global Phase III CLARITY-Gastric01 trial. The study demonstrated statistically significant overall survival improvement in second-line and beyond CLDN18.2-positive advanced gastric cancer patients versus investigator's choice, with a safety profile consistent with prior studies and no new safety signals identified. The company projects peak annual sales of USD 3-5 billion for the drug.</p><p>Despite the strongly positive clinical data, the stock has exhibited a classic sell-the-news pattern, declining 5.59% on July 28 when results were announced and continuing lower, suggesting the market had already priced in the expected outcome ahead of the readout.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1167820107","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167820107","pubTimestamp":1785289802,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 29, KEYMED BIO-B fell 5.38% in regular trading, trading at 74.0 HKD/share with turnover of approximately 51.91 million HKD, extending the prior session's decline.On the news front, the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"走势警报|KEYMED BIO-B 常规交易下跌 5.38%，CMG901 III 期积极数据引发消息抛售压力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"On July 29, KEYMED BIO-B fell 5.38% in regular trading, trading at 74.0 HKD/share with turnover of approximately 51.91 million HKD, extending the prior session's decline.On the news front, the company previously announced that its CLDN18.2-targeting antibody-drug conjugate CMG901, co-developed with AstraZeneca, achieved positive topline results in the global Phase III CLARITY-Gastric01 trial. The study demonstrated statistically significant overall survival improvement in second-line and beyond CLDN18.2-positive advanced gastric cancer patients versus investigator's choice, with a safety profile consistent with prior studies and no new safety signals identified. The company projects peak annual sales of USD 3-5 billion for the drug.Despite the strongly positive clinical data, the stock has exhibited a classic sell-the-news pattern, declining 5.59% on July 28 when results were announced and continuing lower, suggesting the market had already priced in the expected outcome ahead of the readout.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167820107","isCrawlerRequest":true}